This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
I never remove cuticles. I know they ruin an otherwise perfectly polished manicure, BUT, those cuticles are there for a reason. They prevent bacteria and other nasty stuff from entering our nails. Kind of a good reason to keep them there, don’t you agree? Maybe not. Doesn’t matter. I’m not gonna jump on my soapbox […] The post How Does Nail Cuticle Remover Work?
CAGE Bio, Inc. is initiating a Phase 2b dose-ranging trial for its CGB-500 (1% tofacitinib), a topical Janus kinase (JAK) inhibitor ointment for moderate to severe atopic dermatitis (AD) and low body surface area (BSA) involvement. CGB-500 was developed using CAGE Bio’s proprietary ionic liquid technology. CGB-500 delivers medicine directly through the skin, with minimal systemic exposure.
At the inaugural Horizons in Advanced Practice meeting, Lakshi Aldredge, MSN, ANP-BC, reviewed complex cases on AD and PsO and the role of PAs and NPs in advancing patient care.
Erectile dysfunction (ED) is a common concern affecting many men. If you are looking for an effective way to treat erectile dysfunction, the innovative OrthoGold Acoustic Wave Therapy at Fairlawn Aesthetic MD may be the ideal solution for you. Therapy for Erectile Dysfunction: The OrthoGold Advantage One of the most advanced therapies for erectile dysfunction available today is the OrthoGold Acoustic Wave Therapy.
C&T's Consumer Pulse report on the socials uncovers emerging searches and hashtags related to cosmetics. Here, we expand on those themes. This edition includes: Mixsoon's K-Beauty Bean Ferment, Forge's Tallow skin care for men, Spate's 2025 predictions.
The need for support for beauty professionals in the Los Angeles area is urgent. Here's how you can request aid or donate to those impacted by the wildfires in Los Angeles.
A panelist discusses how this patient's history of chronic kidney disease, diabetes, and psychological stress are significant contributing factors to his prurigo nodularis, necessitating a comprehensive treatment approach that addresses both the underlying conditions and the itch-scratch cycle.
The global demand for cosmetic procedures has surged in recent years. The American Society of Plastic Surgeons reported more than 1.5 million cosmetic procedures performed in 2023 in the United States, with injectables like Botox and dermal fillers topping the charts. Unfortunately, this growth has attracted unscrupulous individuals and businesses eager to exploit consumers’ desires for profit.
Hoth Therapeutics, Inc.s HT-001 showed promising interim safety and efficacy results from its Phase 2a clinical trial addressing skin toxicities linked to Epidermal Growth Factor Receptor Inhibitors (EGFRi) in cancer patients. HT-001 topical gel isanticipated to inhibit recruitment and activation of immune cells, reducing inflammation. Fully 100% of patients in Cohort 1 achieved the primary efficacy endpoint of an Acneiform Rash Investigator Global Assessment Scale (ARIGA) score 1, showing signi
Rezpegaldesleukin, a novel IL-2 receptor agonist, enters phase 2b evaluation for atopic dermatitis, aiming to advance therapeutic options for this chronic condition.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content